HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison between two treatment protocols with recombinant human erythropoietin (rHuEpo) in the treatment of late anemia in neonates with Rh-isoimmunization.

AbstractOBJECTIVE:
[corrected] The Rh-hemolytic disease can lead to a late anemia by hemolytic and hyporigenerative mechanism. We compared the effectiveness of rHuEPO in two care protocols that differ for doses of rHuEPO administrated and for timing of administration.
METHODS:
A cohort of 14 neonates was investigated. The neonates were treated with two different protocols. Protocol A: a dose of 200 U/kg/day of rHuEpo administered subcutaneously starting from the end of the second week of life; Protocol B: a dose of 400 U/kg/day of rHuEpo administered subcutaneously starting from the end of the first week of life.
RESULTS:
The hematocrit values in the protocol A group decreased during treatment (32,5% vs 25,2%), whereas the hematocrit value in protocol B group remained almost stable (38,7% vs 42,8%). The mean numbers of platelets remained stable in both groups while neutrophils increased in protocol A group and decreased in protocol B (p<0,05). Reticulocyte count increased during treatment in both groups, although only in protocol B group it was statistically significative (p<0,05).
CONCLUSIONS:
Our results suggest a similar efficacy between the two treatment protocols. Increasing doses of rHuEPO do not seem enhancing their effectiveness and the incidence of side effects.
AuthorsA A Zuppa, G Alighieri, A Fracchiolla, P Catenazzi, A D'Antuono, R Riccardi, M Cavani, C Romagnoli
JournalLa Pediatria medica e chirurgica : Medical and surgical pediatrics (Pediatr Med Chir) 2012 Jul-Aug Vol. 34 Issue 4 Pg. 186-91 ISSN: 0391-5387 [Print] Italy
PMID23173411 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Erythropoietin
Topics
  • Algorithms
  • Anemia, Neonatal (drug therapy, etiology)
  • Cohort Studies
  • Erythropoietin (administration & dosage)
  • Hematocrit
  • Humans
  • Infant, Newborn
  • Injections, Subcutaneous
  • Reticulocyte Count
  • Rh Isoimmunization (complications, therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: